The FDA ANDA review nearing completion with only a vial attestation remaining is the most near-term catalyst — approval and commercial launch could transform the company from pre-revenue to revenue-generating. Monitor for FDA decision on the ANDA and any updates on the DARPA contract finalization, as these represent the primary value drivers over the next 3-6 months.
Price Chart
Executive Summary
NRx Pharmaceuticals reported Q2 2026 financial results with a net loss of $18.0M for the six months ended June 30, 2026, compared to a $23.1M loss in the prior-year period. The company highlighted key regulatory progress on its ANDA for preservative-free ketamine, a DARPA contract for NRX-101, and a strengthened cash position of $26.7M following a $22.3M public offering, extending its cash runway to at least one year. The filing is bullish due to the tangible regulatory and funding milestones, though the company remains pre-revenue with operating losses widening.
Key Facts
- Completed first-cycle FDA review of ANDA for preservative-free ketamine with no drug-related major deficiencies; sole remaining item (manufacturer's attestation) submitted.
- Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS; anticipated non-dilutive funding exceeds $11.5 million.
- Closed institutionally-supported underwritten public offering for gross proceeds of $22.3 million, including full exercise of underwriters' option.
- Cash and cash equivalents of $26.7 million as of June 30, 2026, up from $7.8 million at December 31, 2025.
- Net loss for six months ended June 30, 2026 was $18.0 million vs $23.1 million in prior-year period; net operating loss was $11.3 million vs $7.6 million.
- Appointed Glenn Tyson as first Chief Commercial Officer and retained commercial launch team for preservative-free ketamine.
- HOPE Therapeutics expanded clinical footprint with new sites in Florida and became first US commercial site to use Zeta Surgical's FDA-cleared TMS navigation system.
Financial Impact
Cash balance increased by $18.9M from year-end 2025 to $26.7M; net loss improved by $5.1M vs prior-year six-month period; operating loss widened by $3.7M due to R&D and commercial launch costs.
Risk Factors
- ANDA approval is not guaranteed; FDA could still issue additional deficiencies or reject the application.
- Company remains pre-revenue with widening operating losses; cash runway depends on successful commercialization and potential further dilution via the at-the-market offering facility.
- DARPA funding is subject to completion of contracting and may not materialize as anticipated.
- NRX-100 NDA and NRX-101 Phase 2/3 trial are years away from potential approval; clinical failure risk is significant.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-028111 |
| Exhibit: ex_1005774.htm | 0001437749-26-028111 |
| Document: 0001437749-26-028111-index-headers.html | 0001437749-26-028111 |
| Document: 0001437749-26-028111-index.html | 0001437749-26-028111 |
| Document: 0001437749-26-028111.txt | 0001437749-26-028111 |
| 8-K Data (Synthetic) | 0001437749-26-028111 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access